Endurant Capital Management’s Rein Therapeutics RNTX Stock Holding History

Endurant Capital Management’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-13,172	Closed	-$340K	–	74
2020 Q3	$340K	Buy	+13,172	New	+$310K	0.1%	59
2018 Q2	–	Sell	-3,785	Closed	-$615K	–	80
2018 Q1	$615K	Sell	3,785 -515	-12%	-$91.8K	0.23%	63
2017 Q4	$906K	Buy	4,300 +832	+24%	+$199K	0.28%	60
2017 Q3	$928K	Sell	3,468 -987	-22%	-$248K	0.28%	70
2017 Q2	$993K	Buy	+4,455	New	+$978K	0.28%	67

Other funds holding RNTX

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AIIC

AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

GPFA

Game Plan Financial Advisors Westlake, Ohio $269M AUM 28.74% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Endurant Capital Management's RNTX Position: Q4 2020 in Review

Endurant Capital Management sold out of Rein Therapeutics (RNTX) in Q4 2020, closing a stake of 13,172 shares — an estimated $340K sold.

Endurant Capital Management first reported a position in RNTX in Q2 2017 and held it in 5 quarters. The position peaked at $993K in Q2 2017. 30 funds tracked by Wall St. Rank hold RNTX as of Q4 2020.

Endurant Capital Management reported no remaining Rein Therapeutics position as of Q4 2020 after selling out during the quarter.
Endurant Capital Management sold 13,172 Rein Therapeutics shares in Q4 2020, an estimated $340K.
Endurant Capital Management first reported a position in Rein Therapeutics in Q2 2017 and held it in 5 quarters.
Endurant Capital Management's Rein Therapeutics position peaked at $993K in Q2 2017.
30 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2020.

Based on Endurant Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.